For laboratory and research use only. Not for human consumption.
Industry News5 min read

Hims and Noom Launch Peptides: Sermorelin, NAD+ and BPC-157 Next

Hims & Hers and Noom both launched peptide programs this week, and both say BPC-157 and TB-500 are coming. Here is what is confirmed, what the evidence says, and what it means for the research community.

By Peptibase Team•November 20, 2026
Share:
Hims and Noom Launch Peptides: Sermorelin, NAD+ and BPC-157 Next

The Telehealth Giants Showed Up

Two big consumer health companies launched peptide programs in the same week. Noom rolled out a new brand called OpenRx on November 17. Hims & Hers announced Peptides+ on November 18. If you have been researching peptides for a while, the reaction is probably some mix of "told you so" and "oh great, a subscription."

Here is what is actually confirmed, what the evidence says, and why this matters for people who study this stuff. 🧪

What Hims & Hers Launched

According to the company's own press release, Peptides+ starts with up to five treatments, depending on what a provider decides: sermorelin, NAD+, glutathione, vitamin B12 and L-carnitine. Customers have a clinical visit with a licensed provider, who reviews a health history and goals and may prescribe a plan.

The treatments are compounded in the U.S. and dispensed by licensed U.S. pharmacies regulated by state boards of pharmacy. The release does not mention FDA approval for any of them, and it does not list prices.

The line that grabbed the community's attention is this one: "Access to BPC-157 and TB-500 will follow, consistent with regulatory standards." So the two healing peptides everyone has been talking about are coming, just not yet.

What Noom's OpenRx Launched

Noom's release says OpenRx launched on November 17 with two injectables, sermorelin (pitched for muscle support) and NAD+ (pitched for energy). It also launched two oral dissolvable tablets: one combining PT-141, oxytocin and tadalafil for sexual health, and one with oxytocin alone.

Every prescription is written by a licensed clinician and filled through Noom's U.S. 503A pharmacy network, which the company says follows state pharmacy board oversight and USP compounding standards. Again, no specific prices in the release, just a promise of "accessible and transparent pricing."

BPC-157 and TB-500 are described as "under review," with the formulary expected to expand "in the coming months." The company says that review includes safety-signal monitoring, API sourcing checks and adverse event reporting.

Why Now? The HHS Policy

Neither company launched into a vacuum. CNBC notes that an October HHS policy says the FDA will not take enforcement action against certain licensed pharmacies and physicians that compound six unapproved peptides while formal rules are reviewed. CNBC is also clear that this is not formal approval.

STAT's coverage put the tension in its subheadline: despite a lack of safety data, an HHS decision is letting experimental compounds go mainstream. STAT also reports that Hims has a market cap of more than $3.5 billion and Noom is valued at $3.7 billion.

The Evidence Check Nobody Put in the Press Release

Credit where it is due: Hims is unusually candid. CNBC reports the company acknowledged it has "more to learn about how best to use the peptides and how effective they are." Its chief medical officer, Dr. Anant Vinjamoori, said, "We don't have all of this data that we're used to having with compounds like this."

That honesty is useful, because CNBC's reporting on the five launch products is a reality check:

  • NAD+: A 2026 systematic review screened 113 studies and found zero eligible human clinical outcome trials showing IV or intramuscular NAD+ improves anti-aging, energy or wellness endpoints.
  • L-carnitine: A review of 37 trials found participants lost about 2.7 pounds on average.
  • Vitamin B12: Only 3.6% of U.S. adults are B12 deficient, per U.S. survey data cited by CNBC.
  • Glutathione: The FDA received reports of at least 30 patients with adverse events after compounded IV glutathione.

Notice what this says. The mainstream launch lineup is a mix of compounds with thin human outcome data. Sermorelin is the more established name on the list, but even there the pitch is mostly "wellness."

Where BPC-157 and TB-500 Fit

CNBC describes BPC-157 as an unapproved peptide derived from a protein found in human gastric juice and marketed for healing, and notes that most research on it and TB-500 has been in animals, not humans. That matches what we say on the profiles: lots of interesting preclinical data, very little controlled human data.

STAT adds that no randomized controlled trials show these compounds are safe and effective in humans. That is the honest state of play, and it does not change because a bigger company is now selling them.

What This Means for the Research Community

A few takeaways, with some opinion mixed in:

  1. Demand is real. CNBC reports more than 10,000 people signed up for Hims' early access list within 15 days. A category that was dismissed as a biohacker fringe now has mainstream customers.
  2. The gatekeeping model is the new product. You need a consult, a provider decision and a subscription wrapper. For some people that convenience is worth it. For many in the research community, it is the same access question with a new price tag attached.
  3. Regulators are being pulled along. The policy came first, the corporate launches followed, and the formal rulemaking is still ahead. The research community was here years before any of this.
  4. The evidence gap is still the story. More sellers do not mean more human trials. If you read one thing before buying anything, read the actual studies.

If you want to see how these compounds are described in the literature, start with our peptide database, and use the compare tool to see how related compounds stack up, for example sermorelin vs tesamorelin.

The Bottom Line

Big telehealth brands entering peptides is a legitimacy moment for the category and a reminder of how much is still unproven in humans. The next thing to watch is whether the BPC-157 and TB-500 offerings actually launch, and what the formal FDA rulemaking does next.

This article is educational, not medical advice.

Sources

Researching peptides? Track your protocols free.

Pro members save 10% on every shop order, all year, with no cap.

See Pro Benefits

Topics covered:

Hims & HersNoomsermorelinNAD+BPC-157TB-500compounding

Enjoyed this article?

Get an email when we publish a new guide, when something sold out is back, or when a price drops.